Impax loratadine approval
This article was originally published in The Tan Sheet
Executive Summary
Generics firm to begin shipments of loratadine 5 mg/pseudoephedrine 120 mg tablets to Schering-Plough, Wyeth "within days" of FDA's Jan. 30 approval of firm's ANDA (76-050). Impax Labs notes it has been manufacturing Claritin-D 12-Hour equivalent since November. Firm says it received "first-to-file" status with 180 days of generic marketing exclusivity triggered by first shipment. Under an agreement announced last June, Impax will manufacture, supply Schering with Claritin-D 12-Hour for OTC sale; product will reach shelves in early 2003, Schering says (1"The Tan Sheet" July 1, 2002, p. 4). Impax also has licensing, supply agreement with Alavert marketer Wyeth...
You may also be interested in...
Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.